Nothing in this form
shall be construed to imply that the Commission has verified any information contained herein.

If the notification
relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

PART I. REGISTRANT
INFORMATION.

The registrant is Icagen, Inc. (the “Company”). The
address of the Company’s principal executive office is 4222 Emperor Blvd., Suite 350 Research Triangle Park, Durham, North
Carolina 27703.

PART II. RULES
12B-25 (B) AND (C)

If the subject report
could not be filed without unreasonable effort or expense and the Company seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check appropriate box.)

☒ (a) The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion
thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and

☐ (c) The
accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III. NARRATIVE

The Company is unable
to file its Quarterly Report on Form 10-Q for its quarter ended March 31, 2018 by the prescribed date without unreasonable effort
or expense because the Company was unable to compile and review certain information required in order to permit the Company to
file a timely and accurate report on the Company’s financial condition. The Company believes that the quarterly report will
be completed and filed within the fifth day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934,
as amended.

PART IV. OTHER
INFORMATION

(1) Name
and telephone number of person to contact in regard to this notification:

Mark Korb

(919) 941-5206

(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the Company was required to file such report(s)
been filed? If the answer is no, identify report(s).

☒ Yes

☐ No

(3) Is
it anticipated that any significant change in results of operations from the corresponding period for the last quarterly report
will be reflected by the earnings to be included in the subject report or portion thereof?

☒ Yes

☐ No

The Company is unable
to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 because
the Company is still compiling and reviewing information to complete the review of the financial statements for that period; however,
the Company expects that its sales for the quarter ended March 31, 2018 will have decreased significantly as compared to the quarter
ended March 31, 2017 and its net loss will have increased significantly for the quarter ended March 31, 2018 as compared to the
quarter ended March 31, 2017. The Company anticipates that the Quarterly Report on Form 10-Q will be filed on or before the deadline.

2

Icagen, Inc. has caused this notification
to be signed on its behalf by the undersigned thereunto duly authorized.